《大行報告》中信証券:石藥(01093.HK)mRNA新冠疫苗有望短期獲批 予目標價12元評級「買入」
中信証券發表研究報告指出,石藥(01093.HK)首三季業績穩定增長,實現收入、股東應佔基本溢利、股東應佔溢利分別為234.96億、46.24億及44.68億元人民幣,按年增長13.8%、14.5%及3.1%。此外,公司的新冠mRNA疫苗多項臨床研究報告已向國家藥監局藥品審評中心(CDE)提交,兩款新冠小分子藥物展開佈局。
該行認為,石藥的克艾力集採續約造成一定下調壓力,抗腫瘤板塊明年仍有望維持正增長。恩必普拉動神經系統板塊增長,銘覆樂新適應癥注入提升動力。原料藥及功能性食品增勢迅猛,為公司提供穩定現金流。公司研發成果顯著,未來5年內30餘款新品有望上市。
此外,該行將石藥2022至2024年的每股盈利預測由原來的0.53、0.61及0.69元人民幣,下調至0.51、0.57及0.64元人民幣。考慮到公司較強的盈利能力,予其2022年預測市盈率20倍,目標價12元,維持「買入」評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.